See the DrugPatentWatch profile for bosentan

Yes, liver function should be monitored while on bosentan therapy. Bosentan is a medication used to treat pulmonary arterial hypertension, and it has been associated with elevations in liver enzymes [1].

The prescribing information for bosentan recommends monitoring liver function tests before initiating therapy, monthly for the first three months of treatment, and then every three months thereafter [2]. If elevations in liver enzymes are detected, the dose of bosentan may need to be reduced or the medication may need to be discontinued [2].

It is important to note that not all patients who take bosentan will experience elevations in liver enzymes, and the risk may be lower in patients without pre-existing liver disease [3]. However, routine monitoring of liver function is still recommended as a precautionary measure.

In summary, based on the available information, liver function should be monitored while on bosentan therapy to detect any potential elevations in liver enzymes and adjust the treatment accordingly.

Sources:

1. DrugPatentWatch.com. Bosentan. <https://www.drugpatentwatch.com/drugs/bosentan>
2. Tracleer (bosentan) tablets, for oral use. Full Prescribing Information. Actelion Pharmaceuticals US, Inc. May 2021. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021167s033lbl.pdf>
3. Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch DB, et al. Treatment of pulmonary arterial hypertension. Circulation. 2009;119(16):2250-94. doi: 10.1161/CIRCULATIONAHA.108.191337. <https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.108.191337>